Background and Purpose-Prediction rules for the risk of stroke have been proposed. However, most studies were conducted with whites or for secondary prevention, and it is not clear whether these models apply to the Chinese population. The purpose of this study was to construct a simple points-based clinical model for predicting incident stroke among Chinese adults in Taiwan. Methods-We estimated the 10-year risk of stroke in a cohort study of middle-aged and elderly participants who were free from stroke at baseline. Multivariate Cox model-derived coefficients were used to construct the simple points-based clinical and biochemical model and the prediction measures using the area under the receive operating characteristic curve, net reclassification improvement, and integrated discrimination improvement statistics were applied. Results-Of the 3513 participants without stroke at baseline, 240 incident cases of stroke were documented for a median 15.9-year follow-up. Age (8 points), gender (1 point), systolic blood pressure (3 points), diastolic blood pressure (2 points), family history of stroke (1 point), atrial fibrillation (3 points), and diabetes (1 point) were found to significantly predict stroke events. The estimated area under the receive operating characteristic curve for this clinical points-based model was 0.772 (95% CI, 0.744 to 0.799). The discrimination ability of this clinical model was similar to the coefficients-based models and better than available stroke models. 
P revention of stroke and its associated risk factors has been an important public health priority worldwide. Recent clinical trials demonstrated that identifying high-risk individuals and treating primary prevention can substantially prevent the risk of a stroke event, 1,2 providing a rationale for the identification of a high-risk population as well as implementing lifestyle intervention strategies to prevent stroke. The prediction models for the risk of stroke have been helpful to guide screening and interventions and to predict stroke event (Supplemental Table I ; available at http://stroke. ahajournals.org). However, participants in the previous prediction models were recruited among hospital-based patients under specific treatment for conditions such as Type 2 diabetes, 3, 4 hypertension, 5, 6 and atrial fibrillation 7 or from the cross-sectional survey 6, 8, 9 and those with a history of cardiovascular diseases. 4,10 -12 In addition, the associated covariates included uncommon biochemical measures such as proinsulin, lipoprotein(a), 13 or spot urine albumin-creatinine ratio, 4 and the outcomes were only ascertained by self-validation. 14 Moreover, the performance measures using the area under the receiver operating characteristics curve (AUC) were only available for some studies 4, 14, 15 and were limited to whites, 12, 14, 16 and the performance was not compared with other models. Furthermore, constructing a stroke prediction model was motivated by a high stroke risk and hypertension prevalence among the Asia Pacific countries. 17 Therefore, we constructed clinical as well as biochemical prediction models for stroke risk in a prospective community-based cohort study. We aimed to further clarify the performance measures of these models, which provided a points-based chart and nomogram from clinical measures, and compare whether these models outperform the Framingham 16 and the Prospective Cardiovascular Munster (PROCAM) 14 stroke models.
Methods

Study Design and Study Participants
Details of this cohort study have been published previously. 18 -20 Briefly, the Chin-Shan Community Cohort Study began in 1990 by recruiting 1703 men and 1899 women of Chinese ethnicity aged Ն35 years from the town of Chin-Shan, 30 km north of metropolitan Taipei, Taiwan. Information about lifestyle and medical conditions and anthropometric measures was assessed by interview question-naires and physical examinations in 2-year cycles for the initial 6 years; the validity and reliability of the collected data and measurements have been reported in details elsewhere. 20, 21 
Measurement of Clinical, Lifestyle, and Biochemical Markers
The procedures for clinical and biochemical measures have been reported elsewhere. 20 -22 In brief, blood pressure was measured twice in the right arm using a mercury sphygmomanometer with the subject seated comfortably and arms supported and positioned at the level of the heart. The average of the blood pressure measurements was used as described previously. [23] [24] [25] Family history of stroke was coded as a stroke event among first relatives. Smoking habit was defined by current smoking status. Drinking history was defined as a binary variable using the frequency of drinking habits.
All venous blood samples drawn after a 12-hour overnight fast were immediately refrigerated and transported within 6 hours to the National Taiwan University Hospital. Serum samples were then stored at Ϫ70°C before batch assay for levels of total cholesterol, triglyceride, and high-density lipoprotein cholesterol. Standard enzymatic tests for serum cholesterol were used (Merck 14354 and 14366, respectively). Blood samples for glucose analysis were drawn into glass test tubes each containing 80 mol/L fluoride/oxalate reagent after centrifugation by 1500 g for 10 minutes; glucose levels were measured on supernatant by enzymatic assay (Merck 3389 commercial kit) in an Eppendorf 5060 autoanalyzer. The peripheral blood cell analysis was measured using a blood cell counter (Sysmex Cell Counter NE-8000; TOA Medical Electronics Co Ltd, Kobe, Japan).
Follow-Up Strategy and Outcome Ascertainment
Procedures for our documentation of incident stroke have been previously described and validated. 18, 19, 26 Participants with a baseline history of stroke events (nϭ89) were excluded from this study. Incident stroke cases were ascertained according to the following criteria: a sudden neurological symptom of vascular origin that lasted Ͼ24 hours with supporting evidence from the image study; fatal stroke cases were included. Transient ischemic attacks were not included in this study. Deaths were identified from official certificate documents and further verified by house-to-house visits. The cases were confirmed by cardiologists and neurologists; the National Taiwan University Hospital Committee Review Board approved the study protocol.
Statistical Analysis
We used the multivariate Cox proportional hazards model to establish a parsimonious model for predicting risk of stroke, and specified clinical and biochemical variables in the model. This clinical model included 7 significant predictors: age, gender, systolic and diastolic blood pressure, family history of stroke, diagnosis of atrial fibrillation, and diabetes mellitus (fasting glucose Ն126 mg/dL or with hypoglycemic medication history) derived from a multivariate Cox model in which we specified the stepwise method for best subset selection by entering in or removing from the model using a significance level of 0.05. The proportionality assumption was not rejected in the model. We did not include smoking, alcohol intake, or body mass index in the model because of their nonsignificance in the multivariate model. Because smoking, alcohol intake, and history of coronary heart disease are clinically important predictors for the risk of stroke, 5, 11, 14, 15 we examined the incremental predictive value of adding these variables to this model; however, the likelihood ratio test suggested that adding these variables into the model did not improve prediction beyond the clinical model. Thus, our final clinical model did not include smoking, alcohol intake, or history of coronary heart disease. We also tested the goodness of fit of the model using the Hosmer and Lemeshow test 27 and the results showed adequate fit. In addition, we constructed another biochemical model by adding total cholesterol, white blood cell, and fasting glucose level in this clinical model. To check the impact of competing risks of stroke and nonstroke event in this cohort, we followed the methods provided by Lau et al 28 for the cause-specific hazards estimate and the results were similar to the original Cox model.
We constructed the categorization point model according to the clinical and biochemical covariates using the methods suggested by Sullivan and colleagues. 29 First, we categorized each continuous variable into meaningful groups and assigned the point values according to the coefficients from the Cox model; then we summed up the total points by adding 6 variables together for each individual. Second, we determined the probability of diabetes during the following 10 years based on the following formula, Riskϭ1ϪS 0 (t) exp (␤XϪ␤X ) , where S 0 (t) is the average survival rate at time t (eg, tϭ10 years) at the mean values of the risk factor, ␤s are the Cox regression coefficients, Xs are the individual's values on the variables, and X-bar is the means or proportions of the variables. Third, we conducted the internal validation of the prediction model and obtained a bias corrected estimate of the AUC using a 5-fold cross-validation procedure. 30 We randomly split the data into 5 equal parts. For kϭ1, …, to 5, we used the k th part as the validation data set and the remaining 4 parts as the training data set. To adjust for overoptimism in model fitting, we performed variable selection and coefficient estimates for each iteration, and the coefficients were then fixed when tested on the validation data set. Because the results were consistent between validation and all data sets, we reported the estimated coefficients and points systems from the data set. Fourth, we compared the performance of the proposed prediction models with 2 available stroke models from the Framingham 16 and PROCAM 14 studies (the coefficients assigned in Supplemental Table II ). In addition, we provided several additional statistics, including integrated discrimination improvement (IDI) and net reclassification improvement (NRI) 31 for the comparison between clinical and biochemical models because the AUC value is not the best discriminatory statistics for prediction power. [31] [32] [33] The details are described in the Supplemental Materials. Finally, we plotted the Bland-Altman plot for the differences and the averages of predicted risk from the clinical and biochemical models to evaluate the comparability of these 2 models. 34, 35 In brief, the slope of this plot is the comparison of predicted risk: when the slope is zero, the 2 measures have equal discrimination. We also provided the nomogram for the clinical model in predicting the risk of stroke according to the Harrell algorithm 36 implemented in R software.
All statistical tests were 2-sided with a Type I error of 0.05, and probability values of Ͻ0.05 were considered statistically significant. Analyses were performed with SAS Version 9.1 (SAS Institute, Cary, NC), Stata Version 9.1 (Stata Corporation, College Station, Texas), and R Version 2.9.0 (The R Foundation for Statistical Computing).
Results
For the cohort follow-up from 1990 to the end of 2007 (a total of 49 281 person-years, median 15.9 years, interquartile range: 12.8 to 16.9 years), we documented 240 incident cases of stroke (including 189 cases of ischemic and unclassified type and 51 cases of hemorrhagic type). The means and proportions of statistically significant clinical and biochemical measures in the study participants and the Cox multivariate results that included age, gender, systolic and diastolic blood pressure, family history, atrial fibrillation, and diabetes mellitus are shown in Table 1 . Biochemical measures, including total cholesterol, white blood cell count, and fasting glucose, were also included in the biochemical model.
We developed a simple points system to estimate the stroke risk using the baseline survival function at 10 years and the coefficients of the clinical model (Table 2) . Depending on age, up to 8 points were assigned; gender, 1 point; systolic blood pressure, 3 points; diastolic blood pressure, 2 points; family history of stroke, 1 point; atrial fibrillation, 3 points; and diabetes, 1 points. This approach allowed manual esti-mation of 10-year risk of stroke event for each individual as shown in Table 2 . Similarly, the biochemical model including total cholesterol (1 point) and fasting glucose (1 point) was constructed and the estimated risk for stroke event was assigned in Supplemental Table II . By using the simple points system, we determined that 23.5% of the sample had Ͻ1% risk, 49.0% had a 1% to 5% risk, 25.4% had a 5% to 20% risk, and 2.2% had a 20% of higher risk of incident stroke during a 10-year follow-up interval. This clinical pointsbased model has good discrimination ability with an AUC of 0.772 (95% CI, 0.744 to 0.799), which was similar to the biochemical points-based model (AUC, 0.773; 95% CI, 0.746 to 0.800) and the coefficient-based clinical model (0.778; 95% CI, 0.751 to 0.804) and coefficient-based biochemical model (0.779; 95% CI, 0.752 to 0.806); the test statistics were not significant among these 4 models (Pϭ0.25; Supplemental Table IV ). The estimated coefficients in Framingham and PROCAM for stroke were derived in Supplemental Table III . The AUCs from the Framingham and PROCAM stroke models (0.754; 95% CI, 0.726 to 0.783 for Framingham and 0.748; 95% CI, 0.722 to 0.777 for PROCAM) were significantly lower than that from our points-based clinical model (Pϭ0.001; Figure 1 ). The optimal cutoff values for the points-based clinical and biochemical models were set as 8 with a sensitivity of 0.65 and a specificity of 0.75 for the clinical model and a sensitivity of 0.71 and a specificity of 0.69 for the biochemical model (Supplemental Table V ). In addition, the correctly classified proportion of the clinical model was larger than that of the biochemical model (75% versus 69%), whereas both had a similar Youden index value.
Supplemental Figure I shows the Bland-Altman plot for the predicted risk between the clinical and biochemical pointsbased models, and the negative slope (Ϫ0.011, Pϭ0.02) indicated that the clinical model underestimated risk for the high-risk subjects than the biochemical model. We also found that the NRI and IDI values between the clinical and biochemical models were not significant (NRI, Ϫ0.1%, Pϭ0.66; IDI, Ϫ0.4%, Pϭ0.77), and the reclassification table according to these 2 models showed no marked change for the risk stratification (Table 3) , implying the similar discrimination performance between the clinical and biochemical points-based model for the risk of stroke. We provided a nomogram including the 7 clinical covariates for additional calculation tool (Figure 2 ).
Discussion
Using a community-based cohort study, we developed a points-based clinical model to predict 10-year risk of stroke event in Chinese population based on 7 variables: age, gender, systolic and diastolic blood pressure, family history of stroke, atrial fibrillation, and diabetes mellitus. These variables could be relatively easily obtained in clinical practice and the points system we developed is simple to use. The availability of a simple clinical tool to predict future risk of disease, as has been the case for prediction of coronary heart disease 37 and Type 2 diabetes, 21 will improve the prediction of stroke risk, identify high-risk populations, and enhance preventive strategies.
Several stroke prediction models have previously been developed in various populations (Supplemental Table I ). Cross-sectional studies conducted in Spanish hypertensive 7 In addition, based on 7457 men aged 47 to 55 years in Sweden with Ͼ20 years follow-up, age, diabetes, blood pressure, and history of transient ischemic stroke, atrial fibrillation, and smoking were associated with a stroke event. 38 Asian reports on a stroke prediction model are also available. First, a Japanese prediction model including all stroke and coronary events for 19 years on 4098 men and 5255 women, aged 50 years, for a 19-year follow-up period showed age, smoking, systolic blood pressure, and serum cholesterol and glucose were included in the prediction model. 39 Second, a study based on 7209 Hong Kong Chinese with Type 2 diabetes showed that age, glycohemoglobin, spot urine albumin-creatinine ratio, and history of coronary heart disease predicted the stroke risk significantly. 4 Third, from the 9903 Chinese adults in 1 cohort data, Wu and colleagues constructed a gender-specific points-based prediction chart for 10-year risk of ischemic cardiovascular disease, in which age, systolic blood pressure, total cholesterol, diabetes mellitus, and smoking were included in the model. 40 Genderspecific effects of diabetes, cholesterol, and smoking on the risk of ischemic stroke were found among Chinese adults. 40 However, a prediction model specifically designed for the risk of stroke in Chinese adults is not currently available. Our clinical and biochemical models provide a feasible tool for identifying the high-risk individuals at the risk of stroke. Using gender-specific age, systolic blood pressure, antihypertensive medication history, diabetes, smoking, history of cardiovascular disease, atrial fibrillation, and left ventricular hypertrophy, Wolf and colleagues developed a Framingham model to predict stroke incident during 10 years of follow-up in a white population. 16 Assmann and colleagues also constructed the PROCAM model, which included gender, age, systolic blood pressure, smoking, and diabetes status to predict stroke risk in another white population during a 10-year follow-up period and the AUC of this model reached 0.78 for stroke. 14 Using the participants in our study, the AUCs for Framingham and PROCAM models were signifi- cantly lower than our clinical model. The underperformance may be attributed to regional and ethnic variation in predicting the risk of stroke. 41 In addition, our model contained family history of stroke and atrial fibrillation, which improved the prediction ability than other models. Finally, all stroke subtypes as the outcome would make feasible in screening for a general population. Most of the variables included in our model were similar to those in previous risk functions. We found that white cell count, a marker of chronic inflammation, was incorporated into our coefficient-based biochemical model. However, the incremental effect of white cell count did not substantially increase the points-based score. The additional contribution by total cholesterol and glucose was minimal compared with age and blood pressure in our points-based model. Therefore, we argued that the points-based clinical model is sufficient for predicting the risk of stroke in Chinese adults. We also found that the nomogram using these clinical measures was consistent with the chart calculated from the points-based clinical model. In addition, we did not include information on lifestyle factors such as physical activity and smoking because they were not significant predictors of diabetes after adjusting for other risk factors. The role of smoking with regard to stroke prediction has been reported in previous literature. 5, 15, 40 In addition, left ventricular hypertrophy was incorporated into the Framingham stroke model. 16 Our prediction models did not include smoking, left ventricular hypertrophy, or history of coronary heart disease or transient ischemic stroke. These covariates did not increase significantly the likelihood ratio test value in the multivariate Cox model. Some lifestyle and socioeconomic factors such as physical activity, 12 household income, 10 and depression 38, 42 Figure 2. Nomogram for the risk of stroke incidence in the study participants (nϭ3513). The nomogram is used by first locating a participant position on each predictor variable scale. Each scale position has corresponding prognostic points (top axis). All points were summed to a total points value and a vertical line drawn from the total points axis straight down to the 15-year probability of free from stroke events. were associated with the risk of stroke. However, we included family history of stroke and diastolic blood pressure measures, which increased the prediction power significantly. Previous studies also demonstrated that family history of stroke 43 and diastolic blood pressure 13, 41 added to the predictive ability for stroke. Our clinical model had a similar performance measure as the laboratory model. Considering issues of practicality, cost, and feasibility, the clinical model is recommended for the first-line tool for screening high-risk individuals in a primary prevention setting. 44 Furthermore, to simplify risk prediction in office-based practices without blood sampling, the clinical model can be used as a prediction tool for stroke prevention. 37 The AUC value depends on case mix and disease severity and may be sensitive among those with more severe disease. In addition, the AUC value was based on ranks and may not be sensitive in choosing between models. 32 Our study showed that the AUC values between the clinical and biochemical models were not significant (0.772 versus 0.773). Discrimination and calibration statistics, including net reclassification and integrated discrimination statistics, may be helpful for discriminating the predictive measures between models. 31 To our knowledge, this is the first stroke prediction model specifically developed for a community-based Chinese population. Because of the large sample size, the estimates from our prediction models were found to be stable as demonstrated by the internal validation study. Also, the use of a community-based population reduced the possibility of selection bias. However, several potential limitations of this study should be mentioned: First, we included all types of stroke in this study and did not specify ischemic and hemorrhage subtypes, which indicated different profiles of risk factors. Second, we did not include extensive lifestyle, psychosocial, or biomarkers as well as subclinical disease data in the model. Lifestyle and psychosocial factors were helpful for primary prevention. Second, adding biomarkers such as lipoprotein(a) and subclinical diseases may improve the discriminatory ability. 18, 45 However, these biochemical variables are more difficult to measure and interpret in clinical practice. Next, a lack of an independent population in Asia Pacific countries for external validation may not provide an accurate estimate for the model performance, because the internal validation used in this study may overoptimize the model fitting measures. Then, we did not check the temporal validation for the model. However, according to Altman and Royston, 46 incorporating all the available data because of the large sample size may be a better choice, and we may need to wait several years to accrue an adequate number of events in another cohort. Therefore, using all available data is optimal for the prediction model construction. In addition, the healthcare system for stroke in this community-based cohort was consistent, and we ascertained the stroke cases according to medical history and hospitalization record supplemented by image data. The improving diagnostic tools may have a modest influence on stroke ascertainment. Finally, our study population is rather older (average 55 years), and the age effect on stroke explained most of the risk of stroke (8 points), which diminished the magnitude of other important risk factors such as white blood cell, fasting glucose, and total cholesterol values. Further stratified analysis based on a younger age group may be warranted.
In conclusion, we have constructed a simple points-based clinical model for predicting 10-year incidence of stroke risk, and this model performed significantly better than existing Framingham and PROCAM prediction models within an ethnic Chinese group. This simple clinical tool should help identify high-risk populations and improve prevention and treatment strategies for the Chinese population.
